PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50124F61013As03 establish FILL FINISH activities — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 75A50122D00002. Recompete timing centers on the Feb 21, 2027 PoP end — agencies typically plan 12–18 months ahead.

Barda - Aspr / Daappo / Barda Dcma

Awarding office

Glaxosmithkline LLC

Recipient

Feb 21, 2027

PoP end

$15.4M

Obligated

$15.4M

Potential

541714

NAICS

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Glaxosmithkline LLC — $90

Contract facts

Federal

Contract number75A50124F61013

Also listed as75A50122D00002-75A50124F61013

AgencyBarda - Aspr / Daappo / Barda Dcma

Awarding officeBarda - Aspr / Daappo / Barda Dcma

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentGlaxosmithkline LLC

CAGE667E9

UEIFRHTPHMZMX47

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV75A50122D00002

Place of performanceDURHAM NC

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startFeb 27, 2024

PoP end (current)Feb 21, 2027

Obligated$15.4M

Current value$15.4M

Potential value$15.4M

THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) TO SUPPORT THE COVID-19 FEDERAL RESPONSE- MULTI-DOSE VIALS FOR HHS UNDER IDIQ CONTRACT #75A50122D00002. is a federal award for Barda - Aspr / Daappo / Barda Dcma held by Glaxosmithkline LLC. Estimated value $15.4M ($15.4M obligated). Current period of performance ends Feb 21, 2027. Place of performance: DURHAM NC.

THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) TO SUPPORT THE COVID-19 FEDERAL RESPONSE- MULTI-DOSE VIALS FOR HHS UNDER IDIQ CONTRACT #75A50122D00002.

Recompete timing

Public

● Expiring in 184 days

Current PoP ends Feb 21, 2027 (184 days remaining). Agencies typically plan 12–18 months ahead — at 6.0 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same parent · incumbent

75A50125F61019

FILL/FINISH DOD AS03 ADJUVANT CLIN 1006E

$491K

Aug 30, 2026

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06724F0001366

GSK TRAVEL VACCINES

$115K

Dec 31, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75A50124F61013?

75A50124F61013 (As03 establish FILL FINISH activities) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $15.4M, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75A50124F61013?

Barda - Aspr / Daappo / Barda Dcma awarded 75A50124F61013 to Glaxosmithkline LLC (potential $15.4M).

Who is the incumbent on 75A50124F61013?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Feb 21, 2027.

When does Glaxosmithkline LLC’s 75A50124F61013 come up for recompete?

SCOUT tracks a period-of-performance end of Feb 21, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jul 9, 2026